Published in Ann Rheum Dis on August 01, 2002
Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis (2004) 1.80
The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther (2008) 1.33
Increased circulating levels and salivary gland expression of interleukin-18 in patients with Sjögren's syndrome: relationship with autoantibody production and lymphoid organization of the periductal inflammatory infiltrate. Arthritis Res Ther (2004) 1.10
Inhibition of TNF-α protects against hepatic ischemia-reperfusion injury in rats via NF-κB dependent pathway. Naunyn Schmiedebergs Arch Pharmacol (2012) 1.09
Etanercept reduces the serum levels of interleukin-23 and macrophage inflammatory protein-3 alpha in patients with rheumatoid arthritis. Rheumatol Int (2007) 1.02
Synovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritis. Ann Rheum Dis (2004) 1.00
Distinct effects of IL-18 on the engraftment and function of human effector CD8 T cells and regulatory T cells. PLoS One (2008) 0.94
Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12. Ann Rheum Dis (2005) 0.88
Treatment with anti-TNF-alpha antibody infliximab reduces serum IL-15 levels in patients with rheumatoid arthritis. Clin Rheumatol (2006) 0.81
Cellular targets of interleukin-18 in rheumatoid arthritis. Ann Rheum Dis (2007) 0.81
Anti-tumor necrosis factor-alpha antibody treatment reduces serum CXCL16 levels in patients with rheumatoid arthritis. Rheumatol Int (2007) 0.79
Serum macrophage migration inhibitory factor levels are correlated with response to tocilizumab therapy in patients with rheumatoid arthritis. Rheumatol Int (2013) 0.76
Methotrexate as combination partner of TNF inhibitors and tocilizumab. What is reasonable from an immunological viewpoint? Clin Rheumatol (2015) 0.75
Antibodies against cyclic citrullinated peptide don't decrease after 6 months of infliximab treatment in refractory rheumatoid arthritis. Rheumatol Int (2010) 0.75
Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn's Disease. Am J Gastroenterol (2016) 0.75
Selective antibody activation through protease-activated pro-antibodies that mask binding sites with inhibitory domains. Sci Rep (2017) 0.75
Transcriptional profiling of leukocytes from rheumatoid arthritis patients before and after anti-tumor necrosis factor therapy: A comparison of anti-nuclear antibody positive and negative subsets. Exp Ther Med (2017) 0.75
[Methotrexate as combination partner of TNF inhibitors and tocilizumab: what is reasonable from an immunological viewpoint?]. Z Rheumatol (2013) 0.75
Structural parts involved in activation and inactivation of the sodium channel. Nature (1989) 8.72
Inhibition of Bax channel-forming activity by Bcl-2. Science (1997) 5.10
Single channel recordings of K+ currents in squid axons. Nature (1980) 4.48
Cloning, sequencing, and functional analysis of oriL, a herpes simplex virus type 1 origin of DNA synthesis. Mol Cell Biol (1985) 4.14
Potassium and sodium ion current noise in the membrane of the squid giant axon. J Physiol (1975) 4.03
Measurement of the conductance of the sodium channel from current fluctuations at the node of Ranvier. J Physiol (1976) 3.46
Mapping the site of block by tetrodotoxin and saxitoxin of sodium channel II. FEBS Lett (1991) 3.29
The steady state properties of ion exchange membranes with fixed sites. Biophys J (1965) 3.23
Subthreshold behavior and phenomenological impedance of the squid giant axon. J Gen Physiol (1970) 3.02
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis (2011) 2.74
Channel noise in nerve membranes and lipid bilayers. Q Rev Biophys (1975) 2.67
Nonstationary noise analysis and application to patch clamp recordings. Methods Enzymol (1992) 2.60
Pursuing the structure and function of voltage-gated channels. Trends Neurosci (1990) 2.47
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis (2010) 2.40
Gating currents of inactivating and non-inactivating potassium channels expressed in Xenopus oocytes. Pflugers Arch (1991) 2.28
The muscle chloride channel ClC-1 has a double-barreled appearance that is differentially affected in dominant and recessive myotonia. J Gen Physiol (1999) 2.17
Conductance of the sodium channel in myelinated nerve fibres with modified sodium inactivation. J Physiol (1976) 2.15
Lipoprotein(a) serum levels in patients affected by chronic obstructive pulmonary disease. Atherosclerosis (1999) 2.11
The steady-state properties of an ion exchange membrane with mobile sites. Biophys J (1966) 2.09
EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis (2010) 2.09
Plasma endothelin-1 levels, pulmonary hypertension, and lung fibrosis in patients with systemic sclerosis. Am J Med (1995) 2.07
Cross-sectional survey on immunoglobulin E reactivity in 23,077 subjects using an allergenic molecule-based microarray detection system. Clin Exp Allergy (2010) 2.02
Misdiagnosis in fibromyalgia: a multicentre study. Clin Exp Rheumatol (2012) 2.02
Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis (2004) 1.80
Conductance fluctuations from the inactivation process of sodium channels in myelinated nerve fibres. J Physiol (1980) 1.75
Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab (2004) 1.68
Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant (2009) 1.65
Molecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapies. Eur J Nucl Med Mol Imaging (2009) 1.62
Activation and inactivation of homomeric KvLQT1 potassium channels. Biophys J (1998) 1.61
Anticardiolipin antibodies: occurrence in Behçet's syndrome. Ann Rheum Dis (1984) 1.61
Detection of phospholipid phase separation. A multifrequency phase fluorimetry study of 1,6-diphenyl-1,3,5-hexatriene fluorescence. J Biol Chem (1984) 1.58
Leishmania in SLE mimicking an exacerbation. Clin Exp Rheumatol (2006) 1.54
Disposition of metformin (N,N-dimethylbiguanide) in man. Clin Pharmacol Ther (1978) 1.50
Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjögren's syndrome. Arthritis Rheum (2005) 1.49
AMD3100 for urgent PBSC mobilization and allogeneic transplantation from a normal donor after failed marrow harvest. Bone Marrow Transplant (2010) 1.46
Systemic sclerosis and multiple sclerosis. J Neurol (1999) 1.45
Cardiac involvement in Behçet's disease. Cardiology (1998) 1.42
Inward rectifier potassium channels in plants differ from their animal counterparts in response to voltage and channel modulators. Eur Biophys J (1995) 1.42
Cardiolipin and its metabolites move from mitochondria to other cellular membranes during death receptor-mediated apoptosis. Cell Death Differ (2004) 1.42
Structure of the squid axon membrane as derived from charge-pulse relaxation studies in the presence of absorbed lipophilic ions. J Membr Biol (1981) 1.42
Time-resolved fluorescence emission spectra of Laurdan in phospholipid vesicles by multifrequency phase and modulation fluorometry. Cell Mol Biol (1986) 1.41
Do Behçet's syndrome patients with acne and arthritis comprise a true subset? Comment on the article by Hatemi et al. Arthritis Rheum (2009) 1.40
Evidence for the detrimental role of proteolysis during liver preservation in humans. Gastroenterology (1995) 1.40
Biological activity of chitosan: ultrastructural study. Biomaterials (1988) 1.39
Nerve fiber behaviour in heavy water under voltage-clamp. Biophysik (1968) 1.39
Improvement of blood gas levels after calcium-heparin treatment in patients with chronic obstructive pulmonary disease. Thromb Res (1992) 1.38
Pressure dependence of sodium gating currents in the squid giant axon. Eur Biophys J (1984) 1.36
Pressure dependence of the potassium currents of squid giant axon. J Membr Biol (1982) 1.31
Non-stationary fluctuations of the potassium conductance at the node of ranvier of the frog. J Physiol (1984) 1.25
Generating diversity at GABAergic synapses. Trends Neurosci (2001) 1.24
Stringency without ppGpp accumulation. Nature (1981) 1.22
Ultrasound imaging for the rheumatologist. XXV. Sonographic assessment of the knee in patients with gout and calcium pyrophosphate deposition disease. Clin Exp Rheumatol (2010) 1.21
GAT-1, a high-affinity GABA plasma membrane transporter, is localized to neurons and astroglia in the cerebral cortex. J Neurosci (1995) 1.21
Mechanism of block of single protopores of the Torpedo chloride channel ClC-0 by 2-(p-chlorophenoxy)butyric acid (CPB). J Gen Physiol (2001) 1.18
Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst Rev (2007) 1.18
Wrist joint involvement in systemic lupus erythematosus. An ultrasonographic study. Clin Exp Rheumatol (2004) 1.16
Cardiac involvement in patients with Wegener's granulomatosis. Rheumatol Int (2000) 1.14
Recording of gating currents from Xenopus oocytes and gating noise analysis. Methods Enzymol (1992) 1.13
Nerve membrane electrical characteristics near the resting state. Biophysik (1970) 1.12
Gating and flickery block differentially affected by rubidium in homomeric KCNQ1 and heteromeric KCNQ1/KCNE1 potassium channels. Biophys J (2000) 1.12
Influence of partial hepatectomy on the induction of liver microsomal drug-metabolizing enzymes produced by phenobarbital. A biochemical and ultrastructural study. Lab Invest (1970) 1.12
Heterogeneity of glutamatergic and GABAergic release machinery in cerebral cortex. Neuroscience (2007) 1.12
The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. Rheumatology (Oxford) (2008) 1.12
Cardiolipin on the surface of apoptotic cells as a possible trigger for antiphospholipids antibodies. Clin Exp Immunol (2000) 1.11
Immunoregulation of the in vitro anti-HBs antibody synthesis in chronic HBsAg carriers and in recently boosted anti-hepatitis B vaccine recipients. Clin Exp Immunol (1985) 1.10
GAT-3, a high-affinity GABA plasma membrane transporter, is localized to astrocytic processes, and it is not confined to the vicinity of GABAergic synapses in the cerebral cortex. J Neurosci (1996) 1.09
Potassium and sodium current noise from squid axon membranes. Fed Proc (1975) 1.09
The block of Shaker K+ channels by kappa-conotoxin PVIIA is state dependent. J Gen Physiol (1999) 1.09
Relationship between cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol (1997) 1.09
Insulin stimulates endothelin-1 secretion from human endothelial cells and modulates its circulating levels in vivo. J Clin Endocrinol Metab (1995) 1.09
Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol (2000) 1.09
Power Doppler sonography monitoring of synovial perfusion at the wrist joints in patients with rheumatoid arthritis treated with adalimumab. Ann Rheum Dis (2006) 1.08
Accuracy of VirtualTouch Acoustic Radiation Force Impulse (ARFI) imaging for the diagnosis of cirrhosis during liver ultrasonography. Ultraschall Med (2011) 1.08
Dilute aPTT prolongation by antiphospholipid antibodies in patients with liver cirrhosis. Thromb Haemost (1990) 1.07
Immunization with anticardiolipin cofactor (beta-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice. J Autoimmun (1994) 1.06
Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Oncol (1998) 1.06
Bioadhesive microspheres for ophthalmic administration of acyclovir. J Pharm Pharmacol (1997) 1.06
Abl interconnects oncogenic Met and p53 core pathways in cancer cells. Cell Death Differ (2011) 1.05
Pressure dependence of the sodium currents of squid giant axon. J Membr Biol (1982) 1.05
Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis (2005) 1.04
Interleukin-13 in systemic sclerosis: relationship to nailfold capillaroscopy abnormalities. Clin Rheumatol (2003) 1.04
Endogenous expression of the beta1A sodium channel subunit in HEK-293 cells. FEBS Lett (2000) 1.03
Single point mutations of the sodium channel drastically reduce the pore permeability without preventing its gating. Eur Biophys J (1991) 1.03
Voltage noise, current noise and impedance in space clamped squid giant axon. Pflugers Arch (1974) 1.01
PST2238: a new antihypertensive compound that antagonizes the long-term pressor effect of ouabain. J Pharmacol Exp Ther (1998) 1.00
Beyond the oncogene paradigm: understanding complexity in cancerogenesis. Acta Biotheor (2008) 1.00